21245866|assessment|C1516048^C1261322^C0031809^C0679207|start=0|end=10|PROC^ACTI^CONC
21245866|circulating|C0175630|start=14|end=25|CONC
21245866|biomarkers|C0005516|start=26|end=36|PHYS
21245866|potential|C3245505|start=41|end=50|CONC
21245866|pharmacodynamic|C1709518^C0851347|start=51|end=66|PROC^PHEN
21245866|utility|C0582205|start=67|end=74|ORGA
21245866|lymphoma|C0024299|start=92|end=100|DISO
21245866|purpose|C1285529|start=102|end=109|CONC
21245866|treatment efficacy|C0087113|start=111|end=129|CONC
21245866|toxicity|C0600688^C0040539|start=134|end=142|DISO^CONC
21245866|difficult|C0332218|start=147|end=156|CONC
21245866|lymphoma|C0024299|start=171|end=179|DISO
21245866|study|C0947630^C2603343^C0557651^C0008972^C1705923^C1880229|start=198|end=203|PROC^OBJC^CONC
21245866|utility|C0582205|start=209|end=216|ORGA
21245866|circulating|C0175630|start=220|end=231|CONC
21245866|biomarkers|C0005516|start=232|end=242|PHYS
21245866|monitoring|C1516647^C0150369|start=264|end=274|PROC
21245866|treatment efficacy|C0087113|start=275|end=293|CONC
21245866|toxicity|C0600688^C0040539|start=294|end=302|DISO^CONC
21245866|investigated|C1292732|start=308|end=320|CONC
21245866|methods|C0025664^C0449851^C0025663|start=335|end=342|CONC
21245866|circulating|C0175630|start=344|end=355|CONC
21245866|biomarkers|C0005516|start=356|end=366|PHYS
21245866|cell death|C0007587|start=370|end=380|PHYS
21245866|cytokeratin 18|C1416731|start=409|end=423|GENE
21245866|circulating|C0175630|start=437|end=448|CONC
21245866|flt3 ligand|C1333567|start=449|end=460|GENE
21245866|potential|C3245505|start=464|end=473|CONC
21245866|biomarker|C0005516|start=474|end=483|PHYS
21245866|myelosuppression|C0854467|start=487|end=503|DISO
21245866|assessed|C1516048|start=510|end=518|ACTI
21245866|standard|C1548173^C1442989^C2828392^C3272550|start=545|end=553|CONC
21245866|chemotherapy|C0392920^C3665472^C0013217|start=554|end=566|PROC^CONC
21245866|non-hodgkin lymphoma|C0024305^C3539720|start=599|end=619|DISO^CONC
21245866|cytokeratin 18|C1416731|start=621|end=635|GENE
21245866|expressed|C1515670^C1171362^C0017262|start=643|end=652|PHYS
21245866|lymphoma cells|C0883208^C2697951|start=656|end=670|PROC^ANAT
21245866|is a|C1292718|start=674|end=678|CONC
21245866|potential|C3245505|start=679|end=688|CONC
21245866|biomarker|C0005516|start=689|end=698|PHYS
21245866|epithelial|C0221908|start=702|end=712|CONC
21245866|toxicity|C0600688^C0040539|start=713|end=721|DISO^CONC
21245866|setting|C0542559|start=730|end=737|CONC
21245866|tumour|C0027651|start=739|end=745|DISO
21245866|response|C2911692^C1706817^C0871261|start=746|end=754|PHYS^CONC
21245866|assessed|C1516048|start=759|end=767|ACTI
21245866|completion|C1554962^C0205197|start=785|end=795|CONC
21245866|chemotherapy|C0392920^C3665472^C0013217|start=799|end=811|PROC^CONC
21245866|computed tomography|C0040405|start=825|end=844|PROC
21245866|response|C2911692^C1706817^C0871261|start=858|end=866|PHYS^CONC
21245866|baseline|C1442488^C1552824|start=877|end=885|CONC
21245866|level|C0456079^C1547707^C0441889|start=891|end=896|GEOG^CONC
21245866|lymphoma|C0024299|start=929|end=937|DISO
21245866|subtypes|C0449560|start=938|end=946|CONC
21245866|compared|C1707455|start=947|end=955|ACTI
21245866|prognostic|C0220901|start=989|end=999|CONC
21245866|progression|C0242656^C0449258|start=1004|end=1015|DISO^CONC
21245866|free|C1996904^C1880497^C0332296|start=1016|end=1020|CONC
21245866|survival|C0038952^C0220921|start=1021|end=1029|ACTI^CONC
21245866|diffuse large b-cell lymphoma|C0079744|start=1033|end=1062|DISO
21245866|dlbcl|C0079744|start=1064|end=1069|DISO
21245866|decreases|C0547047^C0442797|start=1072|end=1081|CONC
21245866|levels|C0441889|start=1090|end=1096|CONC
21245866|observed|C1441672|start=1102|end=1110|CONC
21245866|week|C0439230^C1561540|start=1124|end=1128|CONC
21245866|chemotherapy|C0392920^C3665472^C0013217|start=1135|end=1147|PROC^CONC
21245866|early|C1279919|start=1156|end=1161|CONC
21245866|predicted|C0681842|start=1176|end=1185|CONC
21245866|long|C1706317^C0205166|start=1190|end=1194|CONC
21245866|remission|C0687702|start=1195|end=1204|DISO
21245866|following|C0332282|start=1205|end=1214|CONC
21245866|therapy|C0039798^C0087111|start=1215|end=1222|PROC^CONC
21245866|dlbcl|C0079744|start=1227|end=1232|DISO
21245866|elevations|C0702240|start=1234|end=1244|CONC
21245866|occurred|C1709305|start=1253|end=1261|ACTI
21245866|cases|C1533148^C0868928|start=1265|end=1270|CONC
21245866|progressive disease|C3539781^C0677932|start=1276|end=1295|DISO
21245866|circulating|C0175630|start=1297|end=1308|CONC
21245866|increased|C0442805^C0205217|start=1314|end=1323|CONC
21245866|chemotherapy|C0392920^C3665472^C0013217|start=1339|end=1351|PROC^CONC
21245866|epithelial|C0221908|start=1406|end=1416|CONC
21245866|toxicity|C0600688^C0040539|start=1417|end=1425|DISO^CONC
21245866|common|C0205214^C3245511^C1522138|start=1439|end=1445|CONC
21245866|terminology|C0600281^C0028275|start=1446|end=1457|CONC
21245866|classification|C0008903^C0008902^C0678229|start=1462|end=1476|ACTI^CONC
21245866|adverse events|C0877248^C1705413|start=1480|end=1494|DISO^CONC
21245866|criteria|C0243161|start=1495|end=1503|CONC
21245866|flt3 ligand|C1333567|start=1505|end=1516|GENE
21245866|elevated|C3163633^C0205250|start=1521|end=1529|CONC
21245866|days|C0439228|start=1541|end=1545|CONC
21245866|chemotherapy|C0392920^C3665472^C0013217|start=1549|end=1561|PROC^CONC
21245866|initiation|C1704686^C0678321^C0589507^C1158830|start=1562|end=1572|PHYS^CONC
21245866|predicted|C0681842|start=1577|end=1586|CONC
21245866|neutropenic sepsis|C0877153|start=1629|end=1647|DISO
21245866|conclusion|C1707478|start=1649|end=1659|CONC
21245866|data|C3245479^C1511726|start=1667|end=1671|DEVI^CONC
21245866|suggest|C1705535|start=1672|end=1679|CONC
21245866|circulating|C0175630|start=1680|end=1691|CONC
21245866|biomarkers|C0005516|start=1692|end=1702|PHYS
21245866|contribute|C1880177|start=1703|end=1713|ACTI
21245866|useful|C3827682|start=1714|end=1720|CONC
21245866|information|C1533716^C1561527^C1561528^C0870705|start=1721|end=1732|CONC
21245866|tumour|C0027651|start=1743|end=1749|DISO
21245866|response|C2911692^C1706817^C0871261|start=1750|end=1758|PHYS^CONC
21245866|toxicity|C0600688^C0040539|start=1763|end=1771|DISO^CONC
21245866|standard|C1548173^C1442989^C2828392^C3272550|start=1794|end=1802|CONC
21245866|chemotherapy|C0392920^C3665472^C0013217|start=1803|end=1815|PROC^CONC
21245866|potential|C3245505|start=1825|end=1834|CONC
21245866|utility|C0582205|start=1835|end=1842|ORGA
21245866|development|C1527148^C0243107^C3272564^C0678723|start=1850|end=1861|PHYS^CONC
21245866|treatment|C1705169^C0039798^C1533734^C3161471^C1522326^C3538994^C0087111|start=1880|end=1889|PROC^CONC
21245866|approaches|C1292724^C0449445|start=1890|end=1900|CONC
21245866|lymphoma|C0024299|start=1904|end=1912|DISO
21245866|biomarkers|C0005516|start=1920|end=1930|PHYS
21245866|tested|C0392366|start=1945|end=1951|CONC
21245866|phase iii trials|C0282461|start=1971|end=1987|PROC
21245866|progress|C1280477^C1272688|start=1991|end=1999|CONC
21245866|qualification|C1709790|start=2006|end=2019|CONC
